Tags

Type your tag names separated by a space and hit enter

The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers.
BMC Neurosci. 2009 Sep 30; 10:125.BN

Abstract

BACKGROUND

The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158 Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE).A total of 223 MCI patients, 345 AD and 253 healthy controls were analyzed. Clinical criteria and neuropsychological tests were used to establish diagnostic groups.The DNA Bank of the University of the Basque Country (UPV-EHU) (Spain) determined COMT Val158 Met and APOE genotypes using real time polymerase chain reaction (rtPCR) and polymerase chain reaction (PCR), and restriction fragment length polymorphism (RFLPs), respectively. Multinomial logistic regression models were used to determine the risk of AD and MCI.

RESULTS

Neither COMT alleles nor genotypes were independent risk factors for AD or MCI. The high activity genotypes (GG and AG) showed a synergistic effect with APOE epsilon4 allele, increasing the risk of AD (OR = 5.96, 95%CI 2.74-12.94, p < 0.001 and OR = 6.71, 95%CI 3.36-13.41, p < 0.001 respectively). In AD patients this effect was greater in women.In MCI patients such as synergistic effect was only found between AG and APOE epsilon4 allele (OR = 3.21 95%CI 1.56-6.63, p = 0.02) and was greater in men (OR = 5.88 95%CI 1.69-20.42, p < 0.01).

CONCLUSION

COMT (Val158 Met) polymorphism is not an independent risk factor for AD or MCI, but shows a synergistic effect with APOE epsilon4 allele that proves greater in women with AD.

Authors+Show Affiliations

Neurology Department, Hospital de Cruces, Baracaldo, Vizcaya, Spain. mfernandezm@meditex.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19793392

Citation

Martínez, Manuel Fernández, et al. "The COMT Val158 Met Polymorphism as an Associated Risk Factor for Alzheimer Disease and Mild Cognitive Impairment in APOE 4 Carriers." BMC Neuroscience, vol. 10, 2009, p. 125.
Martínez MF, Martín XE, Alcelay LG, et al. The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosci. 2009;10:125.
Martínez, M. F., Martín, X. E., Alcelay, L. G., Flores, J. C., Valiente, J. M., Juanbeltz, B. I., Beldarraín, M. A., López, J. M., Gonzalez-Fernández, M. C., Salazar, A. M., Gandarias, R. B., Borda, S. I., Marqués, N. O., Amillano, M. B., Zabaleta, M. C., & de Pancorbo, M. M. (2009). The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neuroscience, 10, 125. https://doi.org/10.1186/1471-2202-10-125
Martínez MF, et al. The COMT Val158 Met Polymorphism as an Associated Risk Factor for Alzheimer Disease and Mild Cognitive Impairment in APOE 4 Carriers. BMC Neurosci. 2009 Sep 30;10:125. PubMed PMID: 19793392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. AU - Martínez,Manuel Fernández, AU - Martín,Xabier Elcoroaristizabal, AU - Alcelay,Luís Galdos, AU - Flores,Jessica Castro, AU - Valiente,Juan María Uterga, AU - Juanbeltz,Begoña Indakoetxea, AU - Beldarraín,María Angeles Gómez, AU - López,Josefa Moraza, AU - Gonzalez-Fernández,María Carmen, AU - Salazar,Ana Molano, AU - Gandarias,Rocio Bereincua, AU - Borda,Sandra Inglés, AU - Marqués,Nuria Ortiz, AU - Amillano,Miryam Barandiarán, AU - Zabaleta,María Carrasco, AU - de Pancorbo,Marian M, Y1 - 2009/09/30/ PY - 2009/02/12/received PY - 2009/09/30/accepted PY - 2009/10/2/entrez PY - 2009/10/2/pubmed PY - 2009/12/16/medline SP - 125 EP - 125 JF - BMC neuroscience JO - BMC Neurosci VL - 10 N2 - BACKGROUND: The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158 Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE).A total of 223 MCI patients, 345 AD and 253 healthy controls were analyzed. Clinical criteria and neuropsychological tests were used to establish diagnostic groups.The DNA Bank of the University of the Basque Country (UPV-EHU) (Spain) determined COMT Val158 Met and APOE genotypes using real time polymerase chain reaction (rtPCR) and polymerase chain reaction (PCR), and restriction fragment length polymorphism (RFLPs), respectively. Multinomial logistic regression models were used to determine the risk of AD and MCI. RESULTS: Neither COMT alleles nor genotypes were independent risk factors for AD or MCI. The high activity genotypes (GG and AG) showed a synergistic effect with APOE epsilon4 allele, increasing the risk of AD (OR = 5.96, 95%CI 2.74-12.94, p < 0.001 and OR = 6.71, 95%CI 3.36-13.41, p < 0.001 respectively). In AD patients this effect was greater in women.In MCI patients such as synergistic effect was only found between AG and APOE epsilon4 allele (OR = 3.21 95%CI 1.56-6.63, p = 0.02) and was greater in men (OR = 5.88 95%CI 1.69-20.42, p < 0.01). CONCLUSION: COMT (Val158 Met) polymorphism is not an independent risk factor for AD or MCI, but shows a synergistic effect with APOE epsilon4 allele that proves greater in women with AD. SN - 1471-2202 UR - https://www.unboundmedicine.com/medline/citation/19793392/The_COMT_Val158_Met_polymorphism_as_an_associated_risk_factor_for_Alzheimer_disease_and_mild_cognitive_impairment_in_APOE_4_carriers_ L2 - https://bmcneurosci.biomedcentral.com/articles/10.1186/1471-2202-10-125 DB - PRIME DP - Unbound Medicine ER -